Predictive Oncology, Inc. (NASDAQ:POAI) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Michael Broadbent - Private Investor Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q1 2023 Earnings Conference Call. [Operator Inst ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Del ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Conference Call Participants Danny Garcia - KSU Brenda Thompson - IBM Operator Good day and thank you for standing by. Welcome to the Predictive Oncology, Inc. Q4 2022 Earnings Conference Call. At this time, all participants are in a liste ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction (IRS Employe ...

Predictive Oncology Inc. (NASDAQ:POAI) Q3 2022 Earnings Conference Call November 11, 2022 12:00 PM ET Company Participants Theresa Ferguson - Investor Relations Raymond Vennare - Chairman and Chief Executive Officer Pamela Bush - Senior Vice President of Strategic Sales and Business Development Bob Myers - Chief Financial Officer and Site Leader, Skyline Medical Conference Call Participants Michael Broadbent - Bedrock Group Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-100 ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-10 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction of incorpora ...

As of November 5, 2021, the registrant had 65,576,334 shares of common stock, par value $0.01 per share outstanding. PREDICTIVE ONCOLOGY INC. TABLE OF CONTENTS | | Page No. | | --- | --- | | PART I. FINANCIAL INFORMATION | | | Item 1. Unaudited Condensed Consolidated Financial Statements | 3 | | Condensed Consolidated Balance Sheets as of September 30, 2021, and December 31, 2020 | 3 | | Condensed Consolidated Statements of Net Loss for the three and nine months ended September 30, 2021, and | | | September ...